These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 32998963)

  • 1. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
    Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
    Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
    Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
    Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
    [No Abstract]   [Full Text] [Related]  

  • 4. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
    Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
    Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
    Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
    Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells.
    Xu N; Yang XF; Xue SL; Tan JW; Li MH; Ye J; Lou XY; Yu Z; Kang LQ; Yan ZQ; Yu L; Chen SN; Wang YT
    Biochem Biophys Res Commun; 2022 Mar; 595():54-61. PubMed ID: 35101664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
    Read JA; Rouce RH; Mo F; Mamonkin M; King KY
    Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.
    Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Chang AH; Feng X; Tan Y
    J Cell Mol Med; 2021 Jan; 25(2):1089-1099. PubMed ID: 33314568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
    Su YL; Wang X; Mann M; Adamus TP; Wang D; Moreira DF; Zhang Z; Ouyang C; He X; Zhang B; Swiderski PM; Forman SJ; Baltimore D; Li L; Marcucci G; Boldin MP; Kortylewski M
    Blood; 2020 Jan; 135(3):167-180. PubMed ID: 31805184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 15. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
    Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
    J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
    Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
    Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
    Aldoss I; Khaled SK; Budde E; Stein AS
    Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A major role for CD4
    Boulch M; Cazaux M; Cuffel A; Ruggiu M; Allain V; Corre B; Loe-Mie Y; Hosten B; Cisternino S; Auvity S; Thieblemont C; Caillat-Zucman S; Bousso P
    Cell Rep Med; 2023 Sep; 4(9):101161. PubMed ID: 37595589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.